Who Supplies Hydrocortisone to India from BELGIUM

To import finished pharmaceutical formulations containing Hydrocortisone into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting detailed product information, including composition, manufacturing process, and stability data. The CDSCO evaluates the safety, efficacy, and quality of the product before granting approval. The timeline for obtaining these approvals can vary but typically ranges from 6 to 12 months. Hydrocortisone formulations under HS Code 30049099 are subject to these regulatory requirements.

Imported Hydrocortisone formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Upon arrival, customs drug inspectors conduct port inspections to verify the authenticity and quality of the shipments. Failure to meet these standards can result in rejection or destruction of the goods.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for imported medicines to ensure quality and safety. Import registration and licenses have become mandatory for all pharmaceutical imports, including finished formulations containing Hydrocortisone. Additionally, the Production-Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Belgium have facilitated smoother trade processes, but compliance with updated regulations remains essential.

India imports finished Hydrocortisone formulations to meet the demand for specific dosage forms and branded products not available domestically. The domestic pharmaceutical industry may lack the capacity to produce certain specialized formulations, leading to reliance on imports. The market size for Hydrocortisone formulations in India is substantial, with a growing demand due to increasing healthcare needs.

The import duty for Hydrocortisone formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, a Social Welfare Surcharge (SWS) of 10%, and an Integrated Goods and Services Tax (IGST) of 12%. This results in a total landed duty of approximately 17.10%. There are no additional duties such as Anti-Dumping Duty or exemptions for Belgium-origin products.

Belgium is a preferred source for Hydrocortisone formulations due to its high-quality manufacturing standards and compliance with international regulations. Belgian manufacturers often offer patented formulations and specialized dosage forms that may not be available from other suppliers. While countries like China, Germany, and the United States also supply Hydrocortisone formulations, Belgium's reputation for quality and reliability gives it a competitive edge in the Indian market.

India imports Hydrocortisone formulations from Belgium due to the availability of patented products, specialized dosage forms, and high-quality manufacturing standards. Belgium's adherence to international regulatory standards and its reputation for reliability make it a preferred source for these formulations.

Compared to other origins like China, Germany, and the United States, Belgium offers superior quality, compliance with international standards, and specialized formulations. While other countries may offer lower prices, Belgium's products justify the higher cost through enhanced quality and reliability.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality control issues, and shipping disruptions. To mitigate these risks, importers should diversify suppliers, maintain adequate inventory levels, and stay informed about regulatory updates.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stock to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) to manage financial risk.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance.
5. 5Regulatory Compliance: Stay updated on import regulations and ensure all necessary licenses and certifications are in place.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Form 40/41: Submit the application for import registration to CDSCO.
3. 3Drug Import License: Obtain a license for importing drugs from CDSCO.
4. 4No Objection Certificate (NOC): If applicable, obtain an NOC from the Ministry of Health.
5. 5Customs Broker: Engage a licensed customs broker for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30049099 to confirm classification and duty rates.

1. 1Certificate of Analysis (CoA): Confirming product quality and compliance.
2. 2Certificate of Pharmaceutical Product (CoPP): Indicating GMP compliance.
3. 3Good Manufacturing Practice (GMP) Certificate: Issued by relevant authorities.
4. 4Drug Master File (DMF): Providing detailed manufacturing information.
5. 5Stability Data: Adhering to ICH Zone IVa/IVb guidelines.
6. 6Free Sale Certificate: Indicating the product is freely sold in the country of origin.
7. 7Manufacturer Authorization: Authorizing the supplier to export the product.

Upon arrival, CDSCO port inspectors collect samples for mandatory batch testing. The testing process includes verifying the product's identity, strength, quality, and purity. Timelines for testing can vary, but results are typically available within 7 to 14 days.